Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has entered into a global exclusive license-in agreement with KOBIOLABS, Inc. (worth up to KRW 205.2B) for three microbiome candidate strains targeting irritable bowel syndrome with diarrhea (IBS-d) and functional health foods.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Execution of License-in Agreement for Microbiome Gut Disease Drug Candidates
- Contract Partner: KOBIOLABS, Inc. (South Korea)
- Agreement Date: March 25, 2026
- Contract Details:
- Secured global exclusive development and commercialization rights for 3 candidate strains improving gut diseases such as IBS-d
- (1) Exclusive development and commercialization rights for live biotherapeutic products (LBPs) for IBS-d
- (2) Exclusive development and commercialization rights for individually approved or general health functional foods
- Total Contract Amount: Up to KRW 205.2B (Upfront fee KRW 1.0B, total milestones up to KRW 204.2B)
- Upfront Fee: KRW 1.0B
- Development Milestones: Up to KRW 7.2B
- Regulatory Approval Milestones: Up to KRW 13.0B
- Sales Milestones: Up to KRW 184.0B (Paid in tranches based on commercial revenue thresholds)
- Contract Term: From agreement date until the expiration date of the latest-expiring patent (or early termination)
- Board Resolution / Fact Confirmation Date: March 25, 2026
- Investment Risk Factors & Key Notes:
- Conditional contract subject to termination in case of development, regulatory, or commercial failure (Celltrion holds no penalty payment obligations upon termination).
- Milestone payments are contingent upon achieving specific milestones at each stage.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Candidate Strain Development Progress and Milestone Achievement
This disclosure details Celltrion’s license-in agreement with KOBIOLABS, Inc. for exclusive global rights to three microbiome candidate strains, making it important to monitor subsequent clinical trial initiations and development milestones. Tracking development and regulatory milestones is essential to confirm project progression and associated financial commitments. Execution updates can be tracked through upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports) under the ‘Ongoing Research and Development Activities’ section or through future regulatory disclosures.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
